What is Organovo Holdings Operating Cash Flow per Share?
Organovo Holdings's operating cash flow per share for the
three
months ended in Dec. 2023 was $-0.39.
Organovo Holdings's operating cash flow per share for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.90.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 14.70% per year.
During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 26.30% per year.
During the past 10 years, the average Operating Cash Flow per Share Growth Rate was 14.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.
The historical rank and industry rank for Organovo Holdings's Operating Cash Flow per Share or its related term are showing as below:
ONVO'
s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -447.4 Med: 14.7 Max: 35
Current: 14.7
During the past 12 years, Organovo Holdings's highest 3-Year average Operating Cash Flow per Share Growth Rate was 35.00% per year. The lowest was -447.40% per year. And the median was 14.70% per year.
ONVO's 3-Year OCF Growth Rate is ranked better than 61.27% of 1242
companies
in the Biotechnology industry
Industry Median: 3.6
vs ONVO: 14.70
Organovo Holdings Operating Cash Flow per Share Historical Data
The historical data trend for Organovo Holdings's Operating Cash Flow per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Organovo Holdings Operating Cash Flow per Share Chart
Competitive Comparison of Organovo Holdings's Operating Cash Flow per Share
For the Biotechnology subindustry, Organovo Holdings's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Organovo Holdings's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Organovo Holdings's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Organovo Holdings's Price-to-Operating-Cash-Flow falls into.
Organovo Holdings Operating Cash Flow per Share Calculation
Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.
Organovo Holdings's Operating Cash Flow per Share for the fiscal year that ended in Mar. 2023 is calculated as
Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.90
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Organovo Holdings Operating Cash Flow per Share Related Terms
Thank you for viewing the detailed overview of Organovo Holdings's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Organovo Holdings (Organovo Holdings) Business Description
Organovo Holdings Inc is a biotechnology company, which designs and creates functional and three-dimensional human tissues for medical research and therapeutic applications. It also develops and commercializes a platform technology for the generation of three-dimensional human tissues that can be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs. The company collaborates with pharmaceutical and academic partners to develop human biological disease models in three dimensions. Organovo's key instrument platform is the NovoGen Bioprinter. The firm's 3-D bioprinting technologies create tissues using living cells and biocompatible hydrogels.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ONVO has been successfully added to your 